German pharmaceutical manufacturer Biontech continues to expand overseas: Another plant is slated to be built in Singapore this year, the company announced today.
A “modern production facility” should enable a global supply of mRNA-based vaccines and a “rapid response to potential future epidemics in Southeast Asia”.
In Singapore, Biontech is also planning to establish a ‘Regional Headquarters’. Biontech also opened its headquarters in the USA.
Construction of the plant will be carried out in Singapore with the support of the Local Economic Development Authority. Biontech assumes the site could go into operation in 2023 and provide up to 80 jobs.
Several hundreds of millions of vaccine doses are planned each year
Biontech announced that the plant will be “outfitted with the latest manufacturing process and digital infrastructure”. There, a “suite of new mRNA vaccines and therapies against infectious diseases and cancer” should be produced. The plant would “be able to produce several hundreds of millions of doses per year as planned, depending on the vaccine in question or the candidate product.”
“Having different points of contact in our production network is an important strategic step for expanding our global presence and manufacturing capabilities,” says Biontech President Ugur Shaheen. The planned mRNA production facility will help “to manufacture and deliver mRNA vaccines and therapies to people around the world”